GlaxoSmithKline is appealing a Delaware federal district judge’s ruling that wiped out a $235 million verdict against Teva Pharmaceuticals for allegedly infringing a patent for the hypertension drug Coreg.

GSK’s Fish & Richardson attorneys on Monday filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit seeking to overturn U.S. District Chief Judge Leonard P. Stark of the District of Delaware’s final judgment last month that Teva’s ”skinny label” for a generic version of Coreg did not induce infringement of GSK’s patent.